Betacell
A resource for physicians established by the Endocrine Society
Text Size:
Search this site:
Email Newsletter
Podcast
Home Page
BetaCell Science
Case Studies
Expert Blogs
Resources
CME
About Us
Mission Statement
Content
Editorial Board
Editorial Contributors
For Patients
Information and Policies
Sign Up For Email Updates
Contact Us
Resources
Sulfonylureas and Secretagogues RSS
Resource Library
General Reviews
Pathophysiology
Interventions
Lifestyle Changes
Metformin
Sulfonylureas and Secretagogues
Insulin
Alpha-Glucosidase Inhibitors (AGIs)
Thiazolidinediones - TZDs
GLP-1s
DPP-4s
Additional Resources
View the Full Resource List
Search Resources
Keyword:
Author:
Category:
All Categories
--------------------
General Reviews
Pathophysiology
Interventions
Additional Resources
Publication date
Earliest:
Format: 2013-05-25
Latest:
Format: 2013-05-25
Home
›
Resources
›
Interventions
›
Sulfonylureas and Secretagogues
Expert-Selected
All Sulfonylureas and Secretagogues
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
Diabetes; 1995 Nov;44(11):1249-58.
PMID: 7589820;
Category:
Interventions
/
Sulfonylureas and Secretagogues
;
Tags:
glycemic control
,
insulin therapy
,
lifestyle changes
,
metformin
,
prediabetes
,
sulfonylureas (SUs)
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
Wright, Alex; Burden, A C Felix; Paisey, Richard B; Cull, Carole A; Holman, Rury R; ,
Diabetes care; 2002 Feb;25(2):330-6.
PMID: 11815505;
Category:
Interventions
/
Sulfonylureas and Secretagogues
;
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner, R C; Cull, C A; Frighi, V; Holman, R R
JAMA : the journal of the American Medical Association; 1999 Jun 2;281(21):2005-12.
PMID: 10359389;
Category:
Interventions
/
Sulfonylureas and Secretagogues
;
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
Matthews, D R; Cull, C A; Stratton, I M; Holman, R R; Turner, R C
Diabetic medicine : a journal of the British Diabetic Association; 1998 Apr;15(4):297-303.
PMID: 9585394;
Category:
Interventions
/
Sulfonylureas and Secretagogues
;
Individual sulfonylureas and serious hypoglycemia in older people.
Shorr, R I; Ray, W A; Daugherty, J R; Griffin, M R
Journal of the American Geriatrics Society; 1996 Jul;44(7):751-5.
PMID: 8675920;
Category:
Interventions
/
Sulfonylureas and Secretagogues
;
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
Diabetes; 1995 Nov;44(11):1249-58.
PMID: 7589820;
Category:
Interventions
/
Sulfonylureas and Secretagogues
;
Tags:
glycemic control
,
insulin therapy
,
lifestyle changes
,
metformin
,
prediabetes
,
sulfonylureas (SUs)
Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.
Rydberg, T; Jönsson, A; Røder, M; Melander, A
Diabetes care; 1994 Sep;17(9):1026-30.
PMID: 7988301;
Category:
Interventions
/
Sulfonylureas and Secretagogues
;
|